A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics

Pharmacokinetics and Pharmacodynamics of Mepolizumab, an Anti-Interleukin-5 Monoclonal Antibody

(2011) Deborah A. Smith et al.   CLINICAL PHARMACOKINETICS

Lebrikizumab Treatment in Adults with Asthma

(2011) Jonathan Corren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

(2010) Nathanael L. Dirks et al.   CLINICAL PHARMACOKINETICS

Subclinical phenotypes of asthma

(2010) Peter Bradding et al.   Current Opinion in Allergy and Clinical Immunology

Molecular Basis for Shared Cytokine Recognition Revealed in the Structure of an Unusually High Affinity Complex between IL-13 and IL-13Rα2

(2010) Patrick J. Lupardus et al.   STRUCTURE

T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma

(2009) Prescott G. Woodruff et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Exhaled nitric oxide in the diagnosis and management of asthma

(2009) Steve Turner   Current Opinion in Allergy and Clinical Immunology

Cluster Analysis and Clinical Asthma Phenotypes

(2008) Pranab Haldar et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Molecular and Structural Basis of Cytokine Receptor Pleiotropy in the Interleukin-4/13 System

(2008) Sherry L. LaPorte et al.   CELL

IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells

(2008) K. Chibana et al.   CLINICAL AND EXPERIMENTAL ALLERGY